Corneal Changes in Estrogen-Dependent Breast Cancer After Hormonal Treatment

Aromatase inhibitors (AI) therapy is the treatment of choice for estrogen receptor-positive breast cancer (BC). While AIs effectively suppress tumor growth, estrogen deprivation may have negative impacts on the eyes. This work evaluated the anterior segment changes in estrogen-dependent BC after hormonal treatment.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

BRAEST CANCER Breast Diseases Breast Neoplasms Dry Eye Dry Eye Syndromes Eye Diseases Lacrimal Apparatus Diseases Neoplasms Neoplasms by Site Skin Diseases Skin and Connective Tissue Diseases

Age range

18 year and older

Sex eligibility

Male

Study type

Interventional

Phase

Phase 4

Primary location

Sohag university

Sohag, Egypt

About this study

Aromatase inhibitors (AI) therapy is an important treatment for estrogen receptor-positive breast cancer (BC). This work evaluated the eye anterior segment changes in estrogen-dependent BC after hormonal treatment.

This cross-sectional study was conducted on female patients aged ≥18 who received treatment for BC. Patients were evaluated by a number of tests to determine the effects on the cornea and the lacrimal system

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Females diagnosed with breast cancer

Exclusion criteria

uncontrolled diabetes , auto immune diseases

Treatment and study plan

hormonal treatment

Drug

hormonal treatment for breast cancer

Primary outcomes

tear break up time test and shirmer test

Time frame: 6 months

these tests done before starting treatment and in follow up after recieving treatment to evaluate the lacrimal function and dry eye

Secondary outcomes

Corneal thickness and endothelium hexagonality

Time frame: 6 months

Corneal thickness and hesagonality were evaluated before and after treatment with aromatase inhibitors

Sponsors and collaborators

Lead sponsor

Sohag University

Other

Registry information

Acronym: breast cancer

Important dates

Study start: 2024
Primary completion: 2025
Study completion: 2025
First posted: Apr 11, 2025
Registry last updated: Apr 11, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Not Yet Recruiting